Table 3.

Risks of kidney outcomes in black versus white ACCORD participants

Outcomes	Development of Microalbuminuria (UAlb≥30 mg/g)a		Development of Macroalbuminuria (UAlb≥300 mg/g)b		Incident CKDa		Kidney Failure or SCr>3.3 mg/dl
N events/total N	1259/5276		496/7164		610/5215		237/8294
N events/total N, black	278/1124		122/1590		111/1180		59/1937
N events/total N, white	981/4152		374/5574		499/4035		178/6357
Median follow-up time, yr	4.4		4.7		4.7		4.7
Incidence rate events per 1000 person-years follow-up (95% confidence interval)	Incidence Rate	P Value	Incidence Rate	P Value	Incidence Rate	P Value	Incidence Rate	P Value
Black	58 (51 to 65)	0.48	16 (14 to 20)	0.18	21 (18 to 26)	0.008	7 (5 to 9)	0.48
White	55 (52 to 58)		14 (13 to 16)		28 (26 to 31)		6 (5 to 7)
	Hazard Ratio	P Value	Hazard Ratio	P Value	Hazard Ratio	P Value	Hazard Ratio	P Value
Unadjusted	1.04 (0.91 to 1.19)	0.53	1.15 (0.94 to 1.41)	0.17	0.76 (0.62 to 0.93)	0.009	1.11 (0.83 to 1.49)	0.50
Model 1	1.01 (0.87 to 1.17)	0.91	1.08 (0.87 to 1.35)	0.50	0.76 (0.60 to 0.95)	0.02	0.94 (0.69 to 1.29)	0.71
Model 2	1.01 (0.87 to 1.17)	0.92	1.13 (0.90 to 1.42)	0.28	0.70 (0.56 to 0.88)	0.002	0.94 (0.68 to 1.31)	0.73
Model 3	1.06 (0.91 to 1.23)	0.48	1.15 (0.92 to 1.45)	0.23	0.72 (0.57 to 0.90)	0.005	0.93 (0.67 to 1.31)	0.69
Model 4	1.05 (0.90 to 1.22)	0.57	1.15 (0.91 to 1.47)	0.25	0.73 (0.57 to 0.92)	0.009	0.90 (0.63 to 1.27)	0.53

Model 1: stratified by glycemia trial, intensive BP trial, standard BP trial, lipid fenofibrate trial, lipid placebo trial, and network. Model 2: stratified by glycemia trial, intensive BP trial, standard BP trial, lipid fenofibrate trial, lipid placebo trial, and network, and adjusts for demographics: age, female, education, and health insurance. Model 3: stratified by glycemia trial, intensive BP trial, standard BP trial, lipid fenofibrate trial, lipid placebo trial, and network, and adjusts for factors in model 2 and for kidney-specific factors: baseline eGFR, microalbuminuria, and macroalbuminuria. Model 4: stratified by glycemia trial, intensive BP trial, standard BP trial, lipid fenofibrate trial, lipid placebo trial, and network, and adjusts for factors in model 3 and for other baseline clinical factors: systolic BP, body mass index, hemoglobin A1c, smoking status, type 2 diabetes duration, history of heart failure, history of cardiovascular disease (myocardial infarction, stroke, revascularization, or angina), history of retinopathy, and baseline use of medications (angiotensin-converting enzymes, angiotensin receptor blockers, insulin, and thiazolidinedione). ACCORD, Action to Control Cardiovascular Risk in Diabetes; UAlb, urinary albumin; SCr, serum creatinine.

^aNo microalbuminuria, macroalbuminuria adjustment in model 3.

^bNo macroalbuminuria adjustment in model 3.